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Abstract
Background: Atypical femoral fractures (AFF) are a rare type of femoral stress fracture recently described,
potentially associated with prolonged bisphosphonate therapy. Evidence-based recommendations regarding
diagnosis and management of these fractures are scarce. The purpose of this study is to propose an algorithm for
the diagnosis and management of AFF.
Methods: We performed a PubMed search of the last ten years using the keywords “atypical femoral fractures” and
identified further articles through an evaluation of the publications cited in these articles. Relevant studies were
included by agreement between researchers, depending on their specialization. Pertinent points of debate were
discussed based on the available literature, allowing for consensus regarding the proposed management algorithm.
Results: Using a systematic approach we performed a scoping review that included a total of 137 articles.
Conclusions: A practical guide for diagnosis and management of AFF based on the current concepts is proposed.
In spite of the impressive large volume of published literature available since AFF were initially identified, the level
of evidence is mostly poor, in particular regarding treatment choice. Therefore, further studies are required.
Background
The World Health Organization considers osteoporosis
to be second only to cardiovascular diseases as a critical
health problem, due to the high prevalence, costs and effect
on quality of life caused by osteoporotic fractures [1, 2].
Osteoporotic fractures account for more disability and
life-years lost (DALYs) than for all sites of cancer, with
the exception of lung cancers [3]. Proximal femoral
fractures are responsible for the most serious conse-
quences of osteoporosis, due to their elevated incidence,
as well as the hospitalization costs and disability following
these fractures, with a financial burden equivalent to car-
diovascular disease [4]. The number of proximal femoral
fractures is expected to increase worldwide due to ageing
of the population [5, 6].
Bisphosphonates (BPs) are the most commonly pre-
scribed medication to reduce bone resorption and prevent
osteoporotic fractures [7–10]. Bisphosphonate therapy has
been associated with adverse events, such as osteonecrosis
of the jaw and atypical femoral fractures (AFF) [11–13].
The latter are tensile stress fractures with defined radio-
graphic features involving the femur from subtrochanteric
to supracondylar flare. The American Society for Bone
and Mineral Research (ASBMR) proposed a set of specific
criteria in order to identify a case as an atypical femoral
fracture (Table 1) [12]. These criteria should differentiate
AFF from “typical” femoral subtrochanteric or diaphyseal
fracture. However, a clear definition of which should be a
“typical” femoral fracture is not given. Osteoporotic frac-
tures are associated with low energy trauma and usually
have a long oblique or spiral pattern. High-energy trauma
fractures are characterized by a typical complex pattern,
with an increased degree of displacement and commin-
ution [14]. A short oblique or transverse fracture of the
femoral shaft can be due to a direct high-energy impact,
such as dashboard injuries; posterior or medial third
wedge fragment is commonly associated with this pattern.
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Barcsa et al. first coined the term “atypical” in 1978 in
his description of fatigue fractures [15], but the first re-
port of bisphosphonate-related femoral fractures was
published by Odvina et al. in 2005, who suggested a
prominent pathogenic role of severe bone turnover sup-
pression caused by these drugs [16]. Since then, numer-
ous case reports and case series, as well as registry-based
studies, described atypical femoral fractures following
low-energy trauma and associated with prolonged use of
BPs [17–24]. Growing concern brought the ASBMR to
assemble a specific task force in order to resolve the
controversy over this issue and publish a position paper
in 2010 [25]. A second report was published by the
ASBMR task force in 2013 in order to review the major
reports that had been published since 2010, focusing
on three aspects of atypical femur fractures: their epi-
demiology, pathogenesis, and medical management [12].
Figures 1 and 2 show the characteristic patterns of both
complete and incomplete AFF.
Another issue concerning the management of AFF is
fracture healing, that seem to depend on several factors,
including pattern of fracture line, particularly short ob-
lique or transverse, varus malreduction at the fracture site,
and suppression of bone turnover [26, 27]. Therefore, the
treatment of AFF presents as a challenge for the ortho-
pedic surgeon [13, 28–31].
The goal of this scoping review is to propose a practical
diagnostic and treatment algorithm for AFF, in order to
help orthopedic surgeons in the management of AFF.
Table 1 2013 ASBMR task force criteria of atypical femoral
fractures
ASBMR criteria: Four of five major criteria should be observed; additional
minor criteria are not necessary for diagnosis but could be observed in
association to the major criteria.
Major - The fracture is associated with minimal or no trauma,
as in a fall from a standing height or less
- The fracture line originates at the lateral cortex and
is substantially transverse in its orientation, although it
may become oblique as it progresses medially across
the femur
- Complete fractures extend through both cortices and
may be associated with a medial spike; incomplete
fractures involve only the lateral cortex
- The fracture is noncomminuted or minimally
comminuted
- Localized periosteal or endosteal thickening of the
lateral cortex is present at the fracture site (“beaking”
or “flaring”)
Minor criteria - Generalized increase in cortical thickness of the
femoral diaphyses
- Unilateral or bilateral prodromal symptoms such as
dull or aching pain in the groin or thigh
- Bilateral incomplete or complete femoral diaphysis
fractures
- Delayed fracture healing
Fractures of the femoral neck, intertrochanteric fractures with spiral
subtrochanteric extension, periprosthetic fractures, and pathological fractures
associated with primary or metastatic bone tumors and miscellaneous bone
diseases (eg, Paget’s disease, fibrous dysplasia) are excluded [12]
Fig. 1 Radiograph of a patient with a complete AFF. Note the
substantially transverse orientation of the fracture line at the lateral
cortex, the medial spike and the generalized cortical thickening
Fig. 2 Radiograph of a patient with an incomplete AFF (a and b, detail).
a. Note the femoral bowing. b. Note the location of the fracture line on
the lateral cortex,and the focal cortical thickening at the fracture site
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Methods
This scoping review began by creating a research group
formed by five specialists in orthopedic surgery and
traumatology, a physiatrist, an endocrinologist, and a
radiologist. All members have expertise in the field of
metabolic bone disease. The research team performing
the scoping review discussed during a preliminary meet-
ing which were the open issues about the appropriate
management for atypical femoral fractures. After that a
secret voting session was performed and it was decided
that all the issues that got more than 50 % of votes
would have been addressed. Therefore, the 4 major
questions that we are going to clarify with this scoping
review are:
1. How do we make diagnosis of AFF?
2. How to perform the evaluation of bone turnover in
patients with AFF?
3. How to manage the contralateral femur in patients
with AFF?
4. What is the decision making process when a AFF
occurs?.
According to Arksey’s recommendations the scoping
review process included the following six key steps: 1)
identification of the research question, 2) identification
of relevant studies, 3) study selection, 4) charting the data,
5) collecting, summarizing, and reporting the results and
6) consultation exercise [32].
To define atypical femoral fractures, we used the cri-
teria proposed by the ASBMR task force in 2010 and in
2013 [12, 25]. The research protocol was based on a
PubMed search between August 2004 and August 2015,
using “atypical femoral fracture” as keyword. Two inde-
pendent researchers performed a basic review of the ti-
tles and abstracts; in case of unrecoverable abstracts, the
full text was directly reviewed. All articles in English,
Spanish or Italian language were considered eligible for
the review. Relevant articles were marked with consensus
between researchers. References cited in the included
articles were also reviewed. The identification of relevant
articles to be included in the review were performed fol-
lowing these criteria:
1) articles published between August 2004 and August
2015. This period was chosen because, to our
knowledge, the first report of the possible
association between BPs use and femoral shaft
fractures was published by Odvina et al. in the end
of 2004 [16].
2) all the articles where the AFF was identified
following criteria that matched those defined by the
ASBMR, including articles published before the
statements of ASBMR.
3) articles who did not met the ASBMR criteria but
considered relevant by researchers in order to
respond to one or more specific research topics
(i.e. imaging of stress fractures).
The flux of information was organized and analyzed
considering the 4 major topics previously mentioned. Fi-
nally, consensus was obtained on key points drawn from
each study.
All authors declare that they have no competing inter-
ests to disclose.
Results
We identified 393 articles from our initial PubMed
search for “atypical femoral fracture”. Of these, 363 were
published since August 2004 and were therefore initially
considered and discussed. A total of 137 articles met the
inclusion criteria and were therefore included and discussed
in this scoping review (Fig. 3). The studies included were
classified according to the study design as follows: 11
observational studies (3 registry cohort studies and 8
case-control studies), 33 case series studies, 79 case reports,
and 14 reviews. The registry cohort studies, 1 based on ad-
ministrative database of Medicare, 1 on National Swedish
Patient Register, and 1 on National Danish Hospital
Discharge Register, investigated about the association
between BPs use and AFF. The case-control studies
aimed to evaluate the risk of AFF among BPs users (1
study), to characterize the patients with AFF (3 studies), to
examine the AFF pathogenesis (2 studies), to define surgical
Fig. 3 Summary of the article selection process
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outcomes of patients who sustained an AFF (1 study), and
to assess the diagnostic utility of DXA examination in indi-
viduals with AFF (1 study).
Diagnosis of AFF
Clinical presentation of atypical femoral fractures
An adequate patient history and physical examination is
essential to make a diagnosis of AFF, particularly in cases
of incomplete fractures. Prodromal thigh or groin pain is
common [14]. The FDA and the European Medicines
Agency (EMA) recommend attention to the appearance
of thigh/groin pain among long-term bisphosphonate
users [14, 33–35]. In these patients thigh/groin pain
could be prodromic of a subsequent fracture, that could
occur 1 week to 2 years later [35]. Severe pain appearing
suddenly after a history of chronic thigh or groin pain is
considered to be pathognomonic of a complete fracture.
Varus deformity of the lower limb or femoral bowing are
also to be assessed as risk factors for AFF [36–39] (Table 2).
It is mandatory to investigate the patient’s history re-
garding prior and current medications as well as the
mechanism of injury (Table 3). The latter, indeed, is one
of the major diagnostic criteria of AFF, which occurs
without prior trauma or following low-energy trauma,
defined as a fall from a standing height or less [12].
Giusti et al. found an association between BPs-related
AFF (BRAFF) and concomitant use of proton pump in-
hibitors (PPI) and glucocorticoids, but the mechanisms
contributing to facilitate the occurrence AFF is not well
known [35].
Other factors seem to be involved in pathogenesis of AFF
even among BPs users (Table 4), such as demographic fac-
tors, race and age. Marcano et al. observed that patients
with AFF were usually younger and more often of Asian
origin than patients treated with BPs without AFF or pa-
tients with osteoporotic proximal femoral fractures [40].
The higher occurrence among Asians may be due to their
geometrical features, as recently suggested by Oh et al. [41,
42]. Some diseases seem to be more common among pa-
tients with AFF. Collagen diseases are the most common
comorbidity observed in AFF in the series described by
Saita et al. [43]. On the other hand, Giusti et al. observed
that chronic pulmonary disease, asthma, rheumatoid
arthritis and diabetes were the most common comorbidi-
ties reported in AFF patients with the total number of
comorbidities higher in patients with a subtrochanteric
fractures than in those with diaphyseal fractures [35].
Imaging of atypical femoral fractures
Several imaging modalities are offered to the diagnosis
of atypical femoral fractures. Standard x-rays of the
femur in anteroposterior and lateral views, are usually
able to identify the fracture and describe its pattern. The
ASBMR task force defined the precise radiological char-
acteristics for AFF (Table 1).
The definition of “substantially transverse” is a cause
of concern. Some authors interpreted it as an angle of
less than 30 degrees from a line drawn perpendicularly
to the lateral femoral cortex [23, 44]. However, focal cor-
tical thickening and a transverse fracture on the lateral
side are the elements with the highest accuracy for diag-
nosis of AFF [45].
Computed tomography (CT), magnetic resonance im-
aging (MRI) and other imaging modalities are of use, par-
ticularly in case of incomplete AFF [46]. CT is usually able
to demonstrate abnormal bone texture and incomplete
fractures [47]. MRI is the most sensitive and specific im-
aging modality to identify stress fractures, which present
as an increased fluid signal [47]. Cortical thickening
can also be observed in AFF [14]. Bone scintigraphy
demonstrated a high ability to early individuate AFF
[48]. Mild radiotracer uptake with endosteal thickening,
along the lateral proximal diaphysis is considered a rela-
tively specific finding in these fractures [49]. Figures 4 and
5 show the bone scintigraphy and MRI findings in an
incomplete AFF.
Several authors have suggested that dual-energy x-ray
absorptiometry (DXA) scans could be useful for the early
detection of AFF [50–54]. The most common findings
associated with AFF are focal cortical changes both
periosteal and endosteal [53]. Therefore, McKenna et al.
Table 2 Risk factors for atypical femoral fractures
- Long time and/or high compliant BPs user
- Proton pump inhibitor or glucocorticoid use
- Genu varus
- Varus/bowed femur
- Contralateral recent AFF
- Collagen disease





- Pulmonary diseases (asthma,
other chronic pulmonary disease)
Medications:
- Bisphosphonate or other
antiresorptive therapy
- Proton pomp inhibitors
- Glucocorticoid therapy
Incomplete fractures:
- Persistent groin or thigh pain
Complete fractures:
- History of groin or thigh pain
(not always)
- Acute pain, limb shortening
and swelling, ecchymosis
Table 4 Pathogenesis of atypical femoral fractures
AFF pathogenesis
Reduced bone turnover BPs and other powered antiresorptive
drugs (i.e. denosumab)
Lower limb geometry Large femoro-tibial alignment (genu varum)
Bowed Femur
Varus neck-shaft angle
Others age, race, drugs, comorbidities
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recommended extending DXA evaluation to the entire
femur in chronic bisphosphonate users [52], considering
the higher reliability to detect AFF in presence of pro-
dromal signs [53].
Evaluation of bone turnover
Theoretically, most of AFF should occur in low bone
turnover, considering that the current pathogenic hypoth-
esis for BPs-related AFF is an accumulation of micro-
cracks in a “frozen” bone with a very low turnover caused
by antiresorptive therapy [12, 25]. This hypothesis is
corroborated by the observation of similar fracture
patterns in congenital bone diseases characterized by
low bone turnover, such as hypophosphatasia or pyc-
nodysosthosis [55, 56].
Schilcher et al. studied the role of low bone turnover
by performing a histological evaluation of eight cases of
AFF, which showed signs of useless attempts of bone re-
modeling in order to heal the bone in the vicinity of the
fracture gap [24]. Tjhia et al., using nanoindentation,
showed higher resistance to plastic deformation and less
heterogeneous elastic properties of bone tissue which
could decrease resistance to propagation of microcracks
in patients with severe suppressed bone turnover (SSBT),
compared to osteoporotic and young individuals [57]. In a
microindentation analysis, Güerri-Fernández et al. ob-
served deteriorated mechanical proprieties of the bone in
patients with AFF, whereas this was not observed among
patient treated with BPs but without AFF; the authors sug-
gested that BPs were not the only factors playing a role in
the development of an AFF [58].
However, the ASBMR Task Force considers the evi-
dence of the association between BPs use and AFF quite
robust [12], with the fracture risk linked to longer dur-
ation and better adherence to therapy [59]. On the other
hand, it must be underlined that the incidence of these
fractures in BP users is extremely low and, not all AFF
occur in BP users [60, 61].
Management of the contralateral femur
AFF affect the contralateral leg in 28 % of cases [12],
with the time between fractures ranging from 1 month
to 4 years [35], but they can also be simultaneous [62].
Therefore, adequate study of the contralateral femur is
Fig. 4 Bone scintigraphy of a case of incomplete AFF
Fig. 5 STIR-weighted MRI of the same case shown in Fig. 4. Note
the increased fluid signal
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mandatory, as recommended also by the EMA and the
FDA [33, 34]. The evaluation of the contralateral femur
should be done during the initial hospital stay, in order
to quickly determine how to treat or to prevent the
contralateral fracture. An X-ray exam of the entire
contralateral femur is advisable, even if prodromal pain
is absent [33].
Decision making about treatment of the fractured femur
Conservative management
Conservative treatment is an option only in case of patient
with incomplete fractures or severe comorbidities. It is
mandatory to stop the ongoing antiresorptive therapy.
Patients who discontinued BPs therapy had a contra-
lateral AFF incidence of 19.3 % in the following three
years, compared with 41.2 % if the BPs were continued
[14]. Schilcher et al. observed that the risk of AFF fell by
70 %/year after discontinuation of BPs [63]. Pharmaco-
logical treatment is essentially based on administration
of calcium and vitamin D supplements, together with
bone anabolic drugs such as teriparatide. This drug
showed to be effective in promoting callus formation even
in cases of nonunion [64]. Many case reports and case
series have shown the effectiveness of teriparatide in both
complete and incomplete AFF [65–74]. In a retrospective
case-control study on the effect of teriparatide in 45 cases
of AFF, Miyakoshi et al. observed a reduction of healing
time and increased union rate [74].
Nonetheless, the results of conservative treatment are
usually poor. Ha et al. published the results of 14 cases
of AFF treated by observation and analgesics. Ten pa-
tients eventually needed a surgical treatment, and none
of the 4 others had total pain relief or signs of complete
healing [75]. Banffy et al. reported only one successful
outcome in 12 conservatively treated incomplete AFF
using a protocol consisting of partial weight bearing and
observation [76]. However, other authors reported good
results using conservative treatment protocols that in-
cluded avoiding weight bearing, vitamin D and calcium
supplementation, and bone forming agents, such as teri-
paratide or strontium ranelate [65, 66, 71, 74, 77–81].
The ASBMR task force recommendations define conser-
vative treatment as limiting or avoiding weight bearing
in addition to medical management of the underlying
disorder [12, 25].
The ASBMR task force summarizes the medical strategy
of AFF as follows: it is reasonable to discontinue BPs, ad-
equate calcium and vitamin D intake should be ensured,
and teriparatide should be considered for those who
appear not to heal with conservative therapy [12].
Surgical management
Femoral subtrochanteric and shaft fractures are usually
treated with intramedullary (IM) nailing or plating. IM
nailing is the treatment of choice for most authors in
both complete and incomplete AFF; in the latter, IM
nailing is invoked as a preventive approach. The prefer-
ence towards IM nailing is explained by the fact that
endochondral repair is usually not achievable with a
plate. When IM nailing is chosen, overreaming of the
medullary canal by at least 2.5 mm larger than the nail
diameter is recommended [25]. Several authors recom-
mend the use of long cephalomedullary interlocking
nails, considering that stress fractures usually occurred
both above and involving an IM interlocking nail used
to treat a prior AFF fracture [41, 82–85]. Extreme caution
is advisable when performing IM nailing in very bowed or
narrow femora, because of increased risk for distal frac-
tures and diaphyseal comminution [29, 84]. Careful identi-
fication of the correct entry point is mandatory, as well as
choosing a thinner nail [82].
Plate fixation could be a substitute in order to avoid
the complications and technical difficulties associated
with IM nailing [24, 69]. A long locking plate could be a
good option when choosing plate fixation, particularly in
the case of fractures associated with SSBT, in which
healing by second intention through a more elastic con-
struct may adequately stimulate fracture healing. Plate-
and-screw constructs are however associated with a high
complication rate in AFF [25, 29]. As a consequence,
their use in AFF is more restricted than IM nailing, even
if some reports have proven their reliability in selected
incomplete and complete AFF [24, 69, 86, 87].
Two different case series studies showed that surgical
outcomes were generally poorer than in patients with
similar fractures not treated with antiresorptive drugs
and were burdened by more complications, such as in-
traoperative fractures, hardware failure, non-union and
delayed union [28, 29]. Of the 42 BP-associated femoral
shaft fractures reported by Prasarn et al. the two most
common complications were hardware failure (13 %)
and intraoperative fracture (21 %) [29].
Another cause of concern is the effect of bisphospho-
nates on fracture healing. A recent systematic review ob-
served that BPs use is associated with delayed union in
fractures of the distal radius and humerus, even if the
latter finding was reported only in one of the 16 articles
included in the review. Moreover, due to the small number
of patients included, the authors were unable to come to
any conclusion regarding the role of BPs use on femoral
fracture healing [88]. However, a database analysis of the
FDA Adverse Event Reporting System (FAERS) concluded
that healing problems of femoral fractures among BPs
users were an unusual complication, considering that most
cases were observed in AFF [30]. Egol et al. found that
complete healing of BRAFF treated with intramedullary
nails was delayed but generally reliable [26].The mean
time to union for AFF ranges from 6 to 12 months
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[13, 26, 29, 35, 89], but cases of nonunion have been
reported [68, 90].
Discussion
The diagnosis of an AFF (Fig. 6) could be straightforward,
if the ASBMR task force criteria are used for reference. If
an AFF pattern is observed, fractures of the femoral neck
or trochanteric area with distal extension, periprosthetic
and pathologic fractures (both tumoral and miscellaneous
bone disease such as Paget disease) should be excluded.
Further assessment of AFF can be done in three steps:
1. Investigation of pathogenic factors of AFF including
bone metabolic disorders (Fig. 7)
2. Evaluation of the contralateral femur (Fig. 8)
3. Decision making about treatment of the fracture (Fig. 9)
Investigation of pathogenic factors of AFF including
evaluation of bone turnover (Fig. 7)
We consider that AFF could be differentiated in two
major subtypes depending on bone turnover: fractures
in individuals with SSBT or without SSBT. In this way,
orthopedic surgeons can make a more appropriate diag-
nosis and perform a better medical and surgical manage-
ment of these fractures.
A thorough patient history, clinical examination and
analysis of appropriate bone biomarkers can offer a gen-
eral idea of the underlying bone metabolism. The guide-
lines published by the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) and the International Osteoporosis Foundation
(IOF) recommend collecting serum calcium and phos-
phorus levels, intact parathyroid hormone (iPTH), 25-OH-
Vitamin D and at least one resorption (i.e. the C-terminal
telopeptide, CTX) and one formation bone biomarker
(i.e. N-terminal propeptide of type-I procollagen, P1NP
or bone alkaline phosphatase) [91]. However, it is advis-
able to complete the evaluation of bone health through
DXA and a complete metabolic assessment, even after
hospital discharge.
Being dependent on the results of the aforementioned
evaluations, we could distinguish patients in “low turnover”,
Fig. 6 Diagnostic algorithm for atypical femoral fractures
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Fig. 7 Evaluation of the state of bone metabolism and its correction. BRAFF = Bisphosphonate-related Atypical Femoral Fracture
Fig. 8 Evaluation of the contralateral femur
Toro et al. BMC Musculoskeletal Disorders  (2016) 17:227 Page 8 of 13
“normal turnover” and “high turnover”. BRAFF should the-
oretically occur in low turnover group. However, Giusti et
al. found that both bone formation and resorption bio-
markers, were in the normal range in most cases (79 and
69.7 % respectively) and were decreased only in a small per-
centage of cases (14 and 18.2 % respectively) [35]. Anyway,
these findings are susceptible to misinterpretation consider-
ing that most of these evaluations were obtained around
the time of fracture, in a period when the bone was healing
and turnover would be expected to be elevated. Thus,
the patients with fractures probably had a false-normal
turnover, which should be more correctly considered as
a hidden low bone turnover.
In case of a low bone turnover AFF, the fracture might
be associated to antiresorptive therapy (i.e. BPs) or genetic
bone disease (i.e. hypophosphatasia). In this group as well
as in case of false-normal turnover, there is a rational to
stop antiresorptive therapy, and to consider anabolic drugs
according to ASBMR [12]. The relationship between
AFF and antiresorptive therapy is most likely related to
the mechanism of action of these drugs, both BPs and
denosumab [92–98], even if they affect osteoclasts in
different ways [99]. BPs bind to hydroxyapatite crystals are
phagocyted by osteoclasts promoting their apoptosis,
thus inhibiting bone resorption [100]. Denosumab, a fully
human monoclonal antibody, binds to RANKL preventing
RANK-RANKL interaction, thus inhibiting osteoclast ac-
tivity [101].
However, medical therapy should be tailored for all pa-
tients, particularly in those with “high turnover”, consider-
ing that this condition could change the diagnosis of AFF
towards other bone disorders (i.e. Paget’s disease of bone).
Furthermore, some authors have hypothesized that
changes in proximal and diaphyseal femoral geometry
played a key role as a major risk factor for AFF [36–39].
Oh et al. suggested that tensile stress caused by femoral
bowing, contributed towards mechanical failure by modi-
fying the femoral biomechanics, which would account for
most cases of AFF (Fig. 10) [41, 42].
Management of the contralateral femur (Fig. 8)
The treatment decision-making is dependent on the type
of fracture (if any) observed in the contralateral femur
and the risk of fracture progression. In case of incom-
plete contralateral fractures, further treatment depends
mostly on the associated symptoms. If the patient has
thigh or groin pain, prophylactic surgery is advised. On
the other hand, when the patient is asymptomatic, con-
servative treatment may be attempted for the first 2 or
3 months, with strict observation in order to quickly
Fig. 9 Fracture treatment decision-making
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perform prophylactic surgery if signs of fracture progres-
sion or non-union occur [14]. In asymptomatic incomplete
fractures associated with a simultaneous contralateral
complete fracture, prophylactic surgery could be the
gold standard to allow early weight bearing, but the ul-
timate decision depends on patient’s preferences. In in-
dividuals with a negative X-ray examination of the
contralateral femur, clinical observation should remain
strict. If thigh or groin pain appears during follow-up,
further investigations such as a bone scan or MRI is
highly recommended. If imaging findings are compatible
with diagnosis of a fracture, a conservative treatment cycle
for up to 2–3 months may be initiated. If pain worsens or
becomes persistent, prophylactic surgery should be con-
sidered. In this case, fracture healing could be evaluated
repeating MRI or bone scans [77]. On the other hand, if
these imaging studies show no signs of fracture, a follow,
up possibly through serial DXA scans, may be performed.
We suggest that in patients who have already sustained an
AFF, careful evaluation of DXA scans of the contralateral
femur is mandatory, performing a long femur scan, that
does not alter proximal femur bone mineral density
(BMD) measurements [52, 102].
Decision making regarding treatment of the fracture
(Fig. 9)
Careful evaluation of the femoral geometry can be helpful
in order to avoid any of the complications observed with
IM nailing. Bridge plating could be useful in patients with
very bowed or narrow femora.
Several authors demonstrated the reliability of non-
operative treatment that should be adapted to each pa-
tient, particularly keeping in mind the bone turnover
status [65, 66, 71, 74, 77–81]. The ASBMR task force
recommended a trial of conservative treatment in pa-
tients with minimal to mild pain, whereas a prophylactic
nailing is indicated in case of painful incomplete fracture
[25]. Prophylactic nailing seems to be the favorite treat-
ment for incomplete fractures [75, 76, 78, 103, 104],
since conservative treatment seems to be less effective
[75, 76] and surgery demonstrated to provide faster
fracture healing and better pain relief [103]. However,
in some patients surgery can be very challenging, and
unsuccessful outcomes were reported in some cases
[83]. In case of conservative treatment, patients should
be followed-up during the next 2 or 3 months, to assess
possible fracture progression, worsening symptoms or
absence of radiological signs of bone healing, that
would make prophylactic surgery necessary [12, 14, 25].
In a review of 14 cases of incomplete fractures man-
aged conservatively, Saleh et al. found that those which
presented a radiolucent line (the “dreaded black line”)
were the most likely to fail [77]. In another review of
65 incomplete AFF, surgery was indicated more com-
monly in subtrochanteric fractures than in diaphyseal
ones [105].
In our opinion and according to the results of several
studies, prophylactic surgery should be the treatment of
choice in those patients who are at high risk for progres-
sion of the AFF, namely those who are on long-term
antiresorptive therapy and/or are highly compliant with
this treatment, PPI or glucocorticoid users, individuals
with a varus neck-shaft angle or a bowed femur (both in
the lateral and anteroposterior plane), patients who have
sustained a contralateral AFF, patients with a transverse
radiolucent line at standard radiographs, patients with a
subtrochanteric fracture, patients with severe or worsen-
ing thigh or groin pain, and patients who failed to improve
with conservative treatment [14, 35–37, 59, 77, 105]. We
provided an operational algorithm for managing AFF that
better summarizes the information discussed in the pre-
ceding sections (Fig. 6).
Our study has some limitations. The effectiveness of
our algorithm could be limited by the lack of evidence
of the available literature. However, we chose the scop-
ing review methodology considering that clinical trials
represent only the 0.76 % of the literature, limiting thus
the utility of systematic reviews and meta-analyses, In-
stead, in this way we analyzed and summarized the vast
majority of the literature. On the other hand, no stan-
dardized tools to define the quality of included studies
were used.
Further studies with a higher level of evidence are
needed in order to address several issues that remain
unresolved. Indeed, we identified three aspects which
we believe require further investigation: the metabolic
characterization of the fracture (which in our opinion
could be an important guide toward diagnosis and
treatment), the identification of further AFF risk assess-
ment tools, and the role of drug anabolic therapy and
other non-pharmacological interventions to enhance AFF
Fig. 10 Modified AFF pathogenic scheme proposed by Oh et al. [41,
42] reprinted with permission of authors
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healing (i.e. therapeutic ultrasound or others form of
mechanical energy).
Conclusions
Atypical femoral fractures are a rare entity of femoral
stress fracture that occur in the region between subtro-
chanteric and supracondylar areas, and that initially in-
volve the lateral femoral cortex. Large efforts have been
made in order to characterize these fractures, from their
clinical presentation and imaging pattern to their patho-
genesis. However, the level of evidence in the available
literature is mostly poor, particularly regarding the choice
of treatment.
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